

Thomas M Caparrotta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1921248/thomas-m-caparrotta-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

239
citations

7
h-index

15
g-index

22
ext. papers

409
ext. citations

9.9
avg, IF

2.76
L-index

#	Paper	IF	Citations
21	Flash monitor initiation is associated with improvements in HbA levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. <i>Diabetologia</i> , 2022 , 65, 159-172	10.3	2
20	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021 , 64, 1320-1331	10.3	9
19	Sodium-Glucose Co-Transporter ² Inhibitors (SGLT2i) Exposure and Outcomes in Type ² Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021 , 12, 991-1028	3.6	8
18	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 2001-2011	10.3	3
17	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021 , 44, 2010-2017	14.6	4
16	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 82-93	18.1	112
15	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021 , 19, 51	11.4	14
14	Glucagon-Like Peptide ¹ Receptor Agonist (GLP1RA) Exposure and Outcomes in Type ² Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021 , 12, 969-989	3.6	1
13	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 1309-1319	10.3	1
12	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004-2017. <i>Diabetologia</i> , 2020 , 63, 1626-1636	10.3	4
11	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland. <i>Diabetes Care</i> , 2020 , 43, 2034-2041	14.6	5
10	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. <i>PLoS Medicine</i> , 2020 , 17, e1003374	11.6	36
9	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
8	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
7	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
6	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
5	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		

4	Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1907-1924	3.8	6
3	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. <i>Diabetologia</i> , 2019 , 62, 621-632	10.3	21
2	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study		3
1	Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study		10